Novel low-dose 3-in-1 blood pressure pill significantly outperforms standard care, study shows
A novel combination of low doses of three anti-hypertensive drugs in a single pill (GMRx2) was found superior to standard care in lowering blood pressure in uncontrolled hypertension patients, according to the VERONICA-Nigeria trial results presented at the ESC Congress 2024 and published in JAMA. GMRx2 showed significant reductions in systolic blood pressure and improved blood pressure control rates, with good tolerability.
Reference News
A study found that GMRx2, a triple combination pill for hypertension, was more effective than standard care, reducing systolic blood pressure by 31 mmHg vs. 26 mmHg. The pill, combining low doses of telmisartan, amlodipine, and indapamide, improved adherence and control rates, with 82% achieving blood pressure control after six months.
George Medicines presents results from two Phase III trials of GMRx2, a novel, low-dose, triple combination pill for hypertension, showing significant BP reduction and improved control rates with good tolerability at ESC Congress 2024.
A 3-in-1 blood pressure pill, GMRx2, containing telmisartan, amlodipine, and indapamide, showed better control of blood pressure in patients compared to standard care, with 81% of patients on the combo pill achieving control versus 55% with standard care after a month. Developed by George Medicines, the pill is under review by the FDA.
Three trials show polypills improve hypertension control, reduce polypharmacy. QUADRO, GMRx2, and VERONICA trials demonstrate efficacy of combination pills in diverse populations.
A novel combination of low doses of three anti-hypertensive drugs in a single pill (GMRx2) was found superior to standard care in lowering blood pressure in uncontrolled hypertension patients, according to the VERONICA-Nigeria trial results presented at the ESC Congress 2024 and published in JAMA. GMRx2 showed significant reductions in systolic blood pressure and improved blood pressure control rates, with good tolerability.
The triple pill GMRx2, containing telmisartan, amlodipine, and indapamide, showed superior blood pressure control compared to standard care in the VERONICA-Nigeria trial. After one month, 81% of participants achieved control with GMRx2 vs. 55% with standard care, with sustained improvement at six months. The study highlights the potential of this strategy to reach the global goal of 80% blood pressure control.